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Abstract
Reliable quantitative evaluation of molecular pathways is critical for both drug discovery and
treatment monitoring. We have modified the CAM assay to quantitatively measure vascular
density, endothelial proliferation, and changes in protein expression in response to anti-angiogenic
and pro-angiogenic agents. This improved CAM assay can correlate changes in vascular density with
changes seen on a molecular level. We expect that these described modifications will result in a
single in vivo assay system, which will improve the ability to investigate molecular mechanisms
underlying the angiogenic response.
Introduction
The application of antiangiogenic agents for cancer ther-
apy may improve the results of conventional anticancer
treatments because of increased tumor specificity and
decreased development of tumor cell resistance [1,2]. The
correlation between increased angiogenesis and poor out-
come has been established in breast cancer, renal cancer,
prostate cancer, colon cancer and melanoma [3]. Recent
clinical trials have provided support for the use of antian-
giogenic agents in oncology. Yang et al. have shown that
single agent bevacizumab (anti-VEGF antibody, Avastin)
can significantly prolong the time to progression of dis-
ease in patients with metastatic renal-cell cancer [4]. In
addition, Giantonio et al. have demonstrated the benefit
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of the combination of bevacizumab and chemotherapy as
treatment for advanced colorectal cancer resulting in
improved survival [5]. The balance between angiogenesis
and antiangiogenesis involves several mechanisms and
pathways in addition to the modulation of VEGF. Identi-
fication and validation of these additional factors will
provide new targets for antiangiogenic strategies [6]. In
order to capitalize on these discoveries, improved assay
systems are needed to screen for novel angiogenesis inhib-
itors and to elucidate their mechanism of action.
Angiogenesis is a complex process that involves an appro-
priate environment of growth factors, extracellular matrix
proteins, proteases, and cell surface integrins to be present
so that the cellular events of adhesion, proteolysis, migra-
tion, invasion and proliferation can occur [7]. This inter-
play of host factors is critical for angiogenesis to proceed.
Any quantitative assay system needs to recapitulate these
components as closely as possible. A variety of in vitro and
in vivo angiogenesis assay systems have been developed to
measure the effect of various agents on endothelial cell
proliferation and blood vessel growth [8]. Many of these
are subjective and qualitative with limited quantitative
potential, and result in variable data from one laboratory
to another. Most are based on isolated cell preparations,
which do not adequately represent the complex host com-
ponents and interactions that occur in vivo. Though in vivo
small animal models are a closer approximation to the
processes seen in humans, they can be time consuming
and expensive especially during the early stages of agent
evaluation and screening. An alternative to small animal
models is the chick chorioallantoic membrane (CAM)
which provides a natural environment of growing blood
vessels and all the components of the complex host inter-
action [9]. However, its utility has been limited due to dif-
ficulty in measuring the angiogenic response to an
experimental compound in an objective and quantifiable
manner, and by the inability to identify the molecular
basis for these changes.
By utilizing novel methods to quantify vascular density
and protein expression, we have adapted the CAM assay to
create an in vivo angiogenesis model system that is rigor-
ously quantitative, amenable to high-throughput screen-
ing, and applicable for the testing of systemic and/or
topical administration of experimental agents. We have
validated this assay with two known inhibitors of angio-
genesis, known to modulate molecular proteins, and have
then used the assay to identify and partially characterize a
novel angiogenesis inhibitor.
Materials and Methods
Eggs
Chick embryos were acquired on embryonic day 10 from
CBT Farms (Chestertown, Maryland) from White Leghorn
chickens and incubated (RX2 Incubator, Lyon Electric,
Chua Vista, California) at 98.6 degrees F and 51 % relative
humidity.
Preparation of the filter disks
Small filter disks (Whatman filter paper #1001 090) were
generated using a standard 6 mm hole puncher and steri-
lized by autoclaving. Two milliliters of Cortisone acetate
solution (3 mg/ml in 95%ethanol; Sigma#C3130) was
evenly pipetted as a thin layer over the filter disks until sat-
urated and allowed to air-dry under a laminar flow hood.
CAM Assay
The CAM assay was performed in an identical fashion as
described by Brooks et al. [15]. Briefly, day 10 eggs were
candled using a hand held egg candler at the blunt end of
the egg to identify the air sac and prominent blood ves-
sels. Using a Dremel model drill (Dremel #750 MiniM-
ite), the CAM was separated from the shell by making a
shallow burr hole at the blunt end on the egg and another
burr hole made perpendicular to the previously identified
blood vessels in the center of the egg. Mild suction was
applied to the blunt end burr hole to displace the air sac
and drop the CAM away from the shell. Fine forceps were
then used to pick away the shell over the false air sac, so
that a window could be made and the CAM identified.
Next, 15 µl of recombinant human b-FGF(R&D Systems,
#233-FB/CF) 2 ug/ml or vehicle (0.1%BSA/PBS) was
pipetted onto a cortisone dried filter disk and the disk
then placed on the CAM in an avascular area. The window
was sealed with sterile Scotch tape and the egg returned to
the incubator.
Systemic Injection of Antagonists
At day 11, a small hole over the site of the previously iden-
tified blood vessels was made using a razor blade. The
overlying shell was removed leaving the underlying white
shell membrane intact. A drop of mineral oil was used to
render the underlying blood vessels transparent. Using a
30-gauge needle, 100 µl of 100 µM fumagillin in 0.1%
DMSO (Sigma-Aldrich, #F6771), 100 µl of 3 mg/ml
LM609 (Chemicon Inc., Temecula, California), 100 µl of
0.1 µM CC5079 (Celgene Corp., Warren, New Jersey) or
100 µl of a carrier solution (0.1% DMSO) was injected
into the blood vessel. Blood seepage was controlled with
a cotton tip applicator, the window covered with sterile
Scotch tape and the egg placed back into the incubator for
48 hours.
CAM fluorescent confocal microscopy
At day 13, a second window was made on the opposite
side of the egg from the original systemic injection site. A
moderately sized blood vessel was identified and injected
with FITC-dextrin 1 mg/ml (Cat#FD-2000S, Sigma) and
placed back into the incubator for 30 minutes. The CAMJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/4
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disks were then harvested and placed into 10% formalin
and stored at +4 degrees C. The CAM disk specimens were
harvested for light photomicroscopy and then viewed
under the Zeiss LSM 5 Pascal confocal fluorescent micro-
scope using the FITC filter at 488 nm. The image was then
analyzed by the Pascal imaging software (Version 2.8 SP1)
so that the mean fluorescent vascular density could be
measured. Images were then filtered to remove low level
background and large parent vessel interference so that
only new vessel blood formation pixel intensity could be
measured.
Standard Blinded Grading
The CAM disks were harvested for light photomicroscopy
and given to three blinded graders for scoring. Scoring was
based from 0 – 4 (0 = no angiogenesis present in CAM, 4
= strong angiogenesis reaction in CAM). Results of three
blinded graders for each group were then scored.
CAM-XTT assay analysis
Twenty-four hours after systemic injection of an inhibitor
or carrier, day 12 eggs were removed from the incubator
so that they could undergo a cell proliferation assay via a
XTT cell proliferation assay kit (Roche Applied Science
Cat#1465015). Five ml of XTT labeling reagent and 0.1 ml
electron coupling reagent were mixed together and 30 µl
applied via pipette onto the CAM disk. A small piece of
sterile Scotch tape was reapplied over the central window
and the eggs were returned to the incubator for 24 hours.
At day 13 the disks were harvested for light photomicros-
copy and the mean spectrophotometric absorbance at 450
nm was measured (reference wavelength 620 nm (Titertek
Multiskan Ascent Plate Reader)).
CAM-Layered Expression Scanning (LES)
After systemic injection of the experimental compound or
control vehicle, day 13 fertilized eggs were removed from
the incubator. The CAM specimens were harvested, placed
into 70% ethanol and stored at -80 degrees C. Layered
Expression Scanning (LES) was performed on the CAM
specimens according to 20/20 Gene Systems' protocols
(20/20 Gene Systems, Gaithersburg, Maryland). After
transfer, total protein bound to the membranes was bioti-
nylated, followed by immuno-detection of the specific
protein of interest. At the end of the assay, biotinylated
total protein was visualized by streptavidin/FITC conju-
gate and specific protein/primary antibody complexes
were visualized by appropriate secondary antibody conju-
gated to Cy3. Fluorescence on the membranes was
detected on a Scan Array Express Microarray Scanner
(Packard Biosciences) and measured by using ScanArray
Express Software (Packard Biosciences). LES used the fol-
lowing antibodies: rabbit anti-MetAP-2 (Zymed Laborato-
ries Inc., 1:100 dilution, Cat#71–7200), rabbit anti-p21
(Zymed Laboratories Inc., 1:100 dilution, Cat#71–1000),
mouse anti-human integrin alpha v beta 3 (Chemicon
Intl., 1:500 dilution, Cat# MAB1976B), and rabbit anti-
caspase-3 (Cell Signaling Technology, 1:500 dilution,
Cat# 9661). Protein/ primary antibody complexes were
detected with appropriate secondary antibodies conju-
gated to Cy3 and analyzed on a Scan Array Express Micro-
array Scanner (Packard Biosciences).
Statistical Analysis
All statistical analyses were performed using InStat soft-
ware (GraphPad Software Inc., San Diego, California) on
a PowerBook G4 (Apple Computer Inc, Cupertino, Cali-
fornia). Student's t test was performed when the standard
deviations between groups were found to be equal. An
Alternate Welch t test or nonparametric Mann-Whitney U
test was performed when the standard deviations between
groups were not equal.
Results
Fluorescent confocal microscopy imaging in the 
chorioallantoic membrane assay
The CAM of the chicken embryo provides a unique model
for investigating the process of new blood vessel forma-
tion and vessel responses to antiangiogenic agents. Prior
studies using the CAM assay have used subjective scoring
as a means to assess angiogenesis after administration of
an antiangiogenic compound [8]. In order to determine if
the use of fluorescently labeled dextran together with con-
focal microscopy was superior to standard scoring sys-
tems, we compared the scoring of CAMs by confocal
microscopy using image analysis software to the standard
methods employed by blinded graders [8]. CAM disks
were treated with an angiogenic stimulant (bFGF) and
placed onto the CAM surface. After systemic injection of
fumagillin, a known antiangiogenic agent which inhibits
endothelial cell growth [10], or a carrier solution, CAM
disks were harvested and imaged using confocal micros-
copy after a second systemic injection of FITC-dextran
into a vessel in the egg (Figure 1B). The images were then
analyzed using image quantification software to calculate
vascular density (Figure 1C). Each CAM disk was also
photographed using light microscopy for standard
blinded grading using an established scoring system [8].
The results of these two methods were then compared. No
difference was found among the three treatment groups
when photographs (Figures 1D,1E and 1F) of the CAM
disks were analyzed by blinded graders using a standard
scoring system [8] (Figure 2A). This finding was due to the
wide variability in the quality of the CAM disks when har-
vested which is a typical finding in these assays. Hemor-
rhage or debris can often obscure a large number of
neovessels not visible under a dissecting microscope and
these are therefore missed in the counting. The use of flu-
orescence and confocal microscopy allowed for better vis-
ualization of neovessels and an objective measurement ofJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/4
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Fluorescent confocal microscopy imaging in the CAM Figure 1
Fluorescent confocal microscopy imaging in the CAM. (A) Representative photomicrograph of a harvested CAM disk 
showing one large parent vessel (arrow) and a few tributaries. (B) Same CAM disk viewed under the Zeiss LSM 5 Pascal confo-
cal fluorescent microscope using the FITC filter at 488 nm following an injection of FITC-dextran showing large parent vessel 
(arrow) as well as many additional branches (asterisks) not visible under photo microscopy. (C) Using a topogram of each flu-
orescent confocal image, pixel intensity was measured by the Pascal imaging software (Version 2.8 SP1). Images were filtered to 
remove low level background and large parent vessel interference so that only new blood vessel formation fluorescent vascular 
density was measured. (D-F) Day 10 eggs (N = 10–12 eggs per group) were divided into three groups and received filter disks 
saturated with vehicle (0.1% BSA/PBS) solution and systemic injection of carrier (0.1% DMSO) solution (D) or bFGF filter disks 
and systemic injection of carrier solution (E) or systemic fumagillin (F). Photomicrographs of CAM disks were given to three 
blinded graders (representative photomicrographs of one CAM disk from each treatment group shown) and scored for vascu-
larization according to the standard 0–4 grading scale [7,8]. (G-I) Same CAM disks as in D-F (above) after systemic injection 
with FITC-dextran.Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/4
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Evaluation of CAM photomicrographs by blinded grader evaluation Figure 2
Evaluation of CAM photomicrographs by blinded grader evaluation. (A) Results of blinded grading evaluation showed 
no difference between the three groups tested. (B) Confocal fluorescent microscopy evaluation of CAM disks. CAM 
disks were scanned under the Zeiss LSM 5 Pascal confocal fluorescent microscope using the FITC filter at 488 nm. A significant 
difference was measured by mean fluorescent vascular density (+/- SEM) between unstimulated CAM disks and stimulated 
CAM disks after systemic injection of a carrier solution (P = 0.004, Student's t test) and between stimulated CAM disks which 
received systemic injection of fumagillin and carrier solution P = 0.015, Student's t test).Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/4
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vascular density by imaging analysis software. Because the
fluorescence allowed true neovessels to be better visual-
ized, a significant difference was observed by fluorescent
confocal microscopy between CAM disks treated with
bFGF with a systemic carrier solution compared to
unstimulated disks. A large decrease in mean fluorescent
vascular density was detected between stimulated CAM
disks and stimulated disks treated with systemic fumagil-
lin (Figure 2B). The use of the confocal system and com-
puter quantification of density, decreased the variability
between measures seen with blinded grading and
improved the sensitivity of vessel detection. It also
allowed for an objective assessment of the changes in vas-
cularity resulting from the administration of various mod-
ulators of angiogenesis.
XTT cell proliferation assay in the CAM assay
We modified the XTT cell proliferation technique to
directly measure endothelial cell proliferation in addition
to changes in vascular density. Previous studies have used
the XTT assay, a tetrazolium – based colorimetric system,
to measure human umbilical vein endothelial cell
(HUVEC) growth in association with anti-angiogenic
compounds [11]. The XTT assay is based on the cleavage
of the yellow tetrazolium salt XTT to form an orange for-
mazen dye by metabolic active cells and mitochondrial
reduction of the XTT reagent in nonviable cells. We meas-
ured the amount of absorbance after the topical applica-
tion of the XTT reagent onto the stimulated CAM disk. We
were able to detect a significant difference between stimu-
lated CAM disks (Figure 3A) and unstimulated disks (P =
0.028, Student T test). A significant decrease in mean
absorbance was also seen in stimulated disks treated with
fumagillin (P  = 0.018, Student's t test) compared to
untreated stimulated disks. There was a significant
decrease in absorbance in stimulated CAM disks treated
with LM609 (P = 0.029, Student's t test) and untreated
stimulated disks.
Layered Expression Scanning (LES) in the CAM assay to 
quantify changes in protein expression and vascular 
density at the molecular level
Layered expression scanning is a new approach to com-
prehensively analyze tissue samples at the molecular level.
This technique employs an array of layered capture mem-
branes coupled to selected antibodies. A molecular profile
is then obtained for a tissue type based on the antibody
selected. We used LES to measure changes in the expres-
sion of proteins known to be involved in the mechanism
of activity of two known inhibitors of angiogenesis (fum-
agillin and LM609) evaluated using the CAM assay. Fol-
lowing CAM disk treatment with bFGF, eggs were treated
with systemic fumagillin or LM609, and the CAM samples
were arrayed onto a glass slide (Figure 4A). Proteins were
then transferred onto a 10-membrane LES stack (Figure
4B).
We specifically probed the membranes for proteins
known to be involved in the mechanism of action of fum-
agillin and LM609: p21, MetAP-2 and alpha v beta3. In
addition, we probed the blots for proteins involved in the
apoptotic cascade. Our results demonstrated that the
amount of p21 was significantly increased (P < 0.0001,
Student's t test) in CAM disks treated with fumagillin (Fig-
ure 4C). MetAP-2 was found to be significantly increased
in CAM disks treated with fumagillin (P = 0.0042, Alter-
nate Welch t test) and LM609 (P  = 0.0253, Alternate
Welch t test), Figure 4D). This data is consistent with the
published literature, which has demonstrated that both
p21 and MetAP-2 are increased in endothelial cells in
response to fumagillin exposure [12,13].
The amount of alpha v beta3 staining was greatest in stim-
ulated CAM disks treated with bFGF. There was a signifi-
cant decrease in the amount of alpha v beta3 in CAM disks
after systemic treatment with fumagillin (P = 0.01, Stu-
dent's T test). Treatment with LM609 did not significantly
reduce the expression of alpha v beta 3 (P  = 0.1376,
Alternate Welch t test) although the values trended lower
than control. Finally, there was a significant decrease in
the amount of cleaved caspase 3 in CAM disks after sys-
temic treatment with fumagillin (P = 0.007, Student's t
test) and LM609 (P = 0.014, Student's t test, Figure 5B).
This finding is consistent with previous data demonstrat-
ing a relationship between fumagillin treatment and inhi-
bition of cleaved caspase-3 [14].
Evaluation of a novel putative antiangiogenic compound
Having validated this new method for quantifying
endothelial cell proliferation in the CAM assay using two
known angiogenesis inhibitors, we next utilized the XTT
assay to evaluate a putative small molecule inhibitor of
angiogenesis, CC5079. Work in our laboratory has dem-
onstrated that CC5079 inhibits endothelial cell prolifera-
tion  in vitro in a dose dependent manner (data not
shown). In order to determine if CC5079 had antiang-
iogenic properties in vivo, we treated day 10 eggs contain-
ing bFGF stimulated disks with either systemic CC5079
(0.1 µM) or a control carrier vehicle (0.1% DMSO) 24
hours after disk placement. The XTT reagent was then
applied topically to the disks 24 hours after systemic injec-
tion and the disks were scored for endothelial cell prolif-
eration using a plate reader. Significant inhibition of
endothelial proliferation was detected in vivo as a result of
systemic delivery of CC5079 using this assay (Figure 3B).
In order to study changes seen at the molecular level in
response to CC5079, we utilized our previously validated
LES technique. Eggs were prepared in the same fashionJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/4
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CAM XTT assay Figure 3
CAM XTT assay. (A) Day 10 eggs (n = 10 eggs per group) were divided into four groups and received filter disks saturated 
with a vehicle solution (0.1% BSA/PBS) and systemic injection of carrier solution (0.1% DMSO) or bFGF filter disks and sys-
temic injection of carrier solution, fumagillin or LM609. CAM disks in all groups then received topical XTT reagent at Day 12. 
Significant differences were observed between stimulated CAM disks and unstimulated disks (P = 0.028, Student's T test) after 
systemic injection of carrier solution and stimulated disks and CAM disks treated with systemic injection of fumagillin (P = 
0.018, Student's t test) and LM609 (P = 0.029, Student's t test). (B) Day 10 eggs were divided into two groups (n = 6 eggs per 
group) and received filter disks saturated with bFGF followed 24 hours later by systemic injection of carrier vehicle alone (0.1% 
DMSO) or carrier containing CC5079. On Day 12 both groups received topical XTT reagent. A significant inhibition of 
endothelial cell proliferation was seen as a result of the systemic delivery of CC5079 compared to control (P = 0.0079, Mann-
Whitney U Test).Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/4
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Layered Expression Scanning (LES) Figure 4
Layered Expression Scanning (LES). (A) Ten disks (nine CAM specimens and one plain filter disk) were arrayed out on a 
glass slide. (B) A series of membranes (Multiblot membrane stack, 20/20 Gene Systems, Inc.) were generated and stained with 
polyclonal antibodies: rabbit anti-p21, rabbit anti-MetAP-2, mouse anti-human integrin alpha v beta 3, rabbit anti-Caspase-3. 
Images were scanned and analyzed on a Scan Array Express Microarray Scanner (Packard Biosciences). Images were corrected 
for total protein and loading correction. (C) LES/Fumagillin pathway. P21 staining was found to be greatest in CAM disks 
stimulated with bFGF and treated with systemic fumagillin. This was found to be highly significant when compared to stimulated 
CAM disks treated with systemic carrier solution (P < 0.0001 by Student's T test). (D) MetAP-2 staining was strongest in CAM 
disks stimulated with bFGF and treated with systemic fumagillin (P = 0.0042, Alternate Welch t test) and systemic LM609 (P = 
0.0253, Alternate Welch t test), compared to stimulated CAM disks treated with systemic carrier.Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/4
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with bFGF stimulated disks and were then treated with
systemic CC5079 (0.1 µM) or carrier vehicle (0.1%
DMSO). Figure 6A,6B,6C,6D demonstrates the measured
changes in protein expression resulting from CC5079
treatment. We found that CC5079 significantly upregu-
lated the expression of p21 (P < 0.0001, Student's t test)
and cleaved caspase 3 (P = 0.019, Alternate Welch t test)
while inhibiting the expression of alpha v beta3 (P  =
0.027, Alternate Welch t test). The effect on MetAP-2 was
not significantly different from the vehicle alone.
Discussion
As antiangiogenic agents begin to show activity in the
clinic, there is increasing interest in angiogenesis inhibi-
tion as a viable means for treating cancer [4,5]. In order to
improve upon these successes, as well as to help guide the
choice of therapeutic combinations, a better understand-
ing of the mechanisms of action and relative degree of
activity of these agents is important. Robust screening
methods are needed which can help in the selection of
compounds that look promising for further evaluation.
Our modifications of the in vivo CAM assay may provide a
useful tool for this purpose.
The creation of a fluorescent angiogram of the CAM is a
simple modification which renders the assay more quan-
titative in the analysis of vascular density than previously
described [15]. In this study, differences between treat-
ment groups could be detected when CAM disks were
scanned under fluorescent confocal microscopy (Figure
2B) and the images analyzed with image analysis software
(LSM 5 Pascal Software, Version 2.8 SP1, Copyright Carl
LES/LM609 pathway Figure 5
LES/LM609 pathway. (A) Alpha v beta 3 staining was most intense in stimulated CAM disks. The difference in staining was 
found to be statistically significant between stimulated CAM disks and disks treated with fumagillin (P = 0.01, Student's t test). 
(B) Cleaved caspase-3 staining was found to be greatest in stimulated disks treated with carrier solution and least in CAM disks 
treated with fumagillin (P = 0.007, Student's t test) and LM609 (P = 0.014, Student's t test).Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/4
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LES/ CC5079 Figure 6
LES/ CC5079. (A) p21 was increased in CAM disks treated with systemic CC 5079 as compared to control (P < 0.0001, Stu-
dent's t test). (B) MetAP-2 trended towards greater expression in CAM disks after systemic CC 5079 injection, but this did not 
reach statistical significance compared to control (P = 0.0787, Student's t test). (C) CC5079 increased the expression of 
cleaved caspase-3 (P = 0.0184, Alternate Welch t test) while (D) inhibiting the expression of alpha v beta 3 (P = 0.0266, Alter-
nate Welch t test).Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/4
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Zeiss 1986–2000). CAM disks stimulated with bFGF
(Figure 1E and 1H) had a greater degree of angiogenesis
than unstimulated disks (Figure 1D and 1G) or disks that
were stimulated but then treated with systemic injection
of fumagillin (Figure 1F and 1I). These differences were
missed by blinded graders (Figure 2A) using standard
scoring systems due to the variability in vessel detection
using this method. When comparing the light photomi-
crographs and FITC angiograms of stimulated CAM disks,
it is apparent that many small blood vessels are not
detected by standard microscopy (Figure 1A,1B). The use
of fluorescent confocal imaging and FITC-dextran injec-
tion can render an obscure CAM disk readable and allows
for the quantitative measurement of fluorescent vascular
density. Of note, we have also used FITC labeled lectin in
similar experiments with equivalent results (data not
shown).
In order to directly quantify changes in endothelial cell
proliferation in vivo, we applied the XTT reagent to the
CAM assay. The XTT assay is based on the cleavage of the
yellow tetrazolium salt XTT to form an orange formazen
dye by metabolically active cells. In our experiments, CAM
disks treated with bFGF and the systemically administered
angiogenesis inhibitors, fumagillin or LM609, showed
significant inhibition of endothelial cell proliferation by
the XTT assay as measured by a decrease in overall mean
absorbance (Figure 3A).
We also tested the putative angiogenesis inhibitor,
CC5079, for activity using the XTT modified CAM assay.
CC5079 is an orally bioavailable agent with in vitro effects
on endothelial cells including inhibition of cytokine
release, inhibition of proliferation, and inhibition of
tubulin polymerization[16]. CC5079 showed a signifi-
cant decrease in mean absorbance in the XTT assay when
compared to untreated bFGF stimulated CAM disks (Fig-
ure 3B). Use of the XTT assay may be a useful method to
quantify endothelial cell proliferation or inhibition in the
CAM assay in a more direct fashion. Such a measurement
is complementary to the measurements obtained using
the FITC-dextran angiograms which quantify vascular
density and can be used to study vessel architecture and
branching.
In developing this new assay system we feel it was impor-
tant not only to be able to quantify the phenotypic
changes in angiogenesis, but also to detect proteonomic
changes responsible for these effects. Layered Expression
Scanning (LES) has been previously used to perform pro-
tein analysis and quantification in tumor samples [17,18].
This technique is based on removing proteins from the tis-
sue samples and presenting them to a thin absorbent
membrane for detection and identification. The tech-
nique is similar to a Western Blot in that the proteins are
more bioavailable to subsequent antibody analysis than
they might otherwise be using approaches such as immu-
nohistochemistry. In addition, LES allows for preserva-
tion of tissue architecture and for multiple blots to be
created from a single sample.
To validate this technique, we investigated a pathway pre-
viously determined to play a role in the mechanism of
action of fumagillin. Fumagillin has been shown to mod-
ulate p21 and methionine peptidase (MetAP-2) [12,13].
Changes in the levels of expression of p21 and MetAP-2
have been shown to correlate with the effects of fumagil-
lin on endothelial cell proliferation [19,20]. Our results
demonstrated that p21 staining was greatest in CAM disks
stimulated with bFGF and treated with systemic fumagil-
lin when compared to controls (Figure 4C). Furthermore,
MetAP-2 staining was greatest in CAM disks stimulated
with bFGF and treated with systemic fumagillin. These
findings are consistent with the published literature and
help to validate this approach [12,13]. We also found that
there was an up regulation of MetAP-2 in disks treated
with LM609 (Figure 4D). The accumulation of the G-1
cyclin-dependent kinase inhibitor p21 is known to be
caused by the activation of the p53 pathway after exposure
to TNP-470, a fumagillin analog [10]. The exact mecha-
nism for the increase in MetAP-2 by fumagillin is
unknown, however previous studies have shown that
MetAP-2 acts as a direct molecular target for TNP-470
[21]. The up regulation of MetAP-2 in association with
LM609 has not been previously described.
There was a significant decrease in the amount of staining
of alpha v beta 3 in CAM disks treated with fumagillin
(Figure 5A). The mechanism of alpha v beta3 down regu-
lation in CAM disks after systemic treated with fumagillin
has not been previously described. Staining for cleaved
caspase-3 was greatest in stimulated CAM disks treated
with systemic carrier. A significantly lower amount of
staining was seen in CAM disks treated with fumagillin
and LM609 (Figure 5B). Both, fumagillin and LM609 are
known to induce apoptosis. Methionine aminopeptidase
(MetAP-2) is known to be the molecular target of
fumagillin. Fumagillin has been shown to inhibit cancer
cell proliferation and MetAP-2 may play a complex role in
tumor cell progression. Previous studies have examined
the expression and function of MetAP-2 in an in vitro
model of human mesothelioma. Fumagillin was found to
induce apoptosis due to early mitochondrial damage in
malignant cells. Transfection of mesothelioma cells with
MetAP-2 anti-sense oligonucleotide induced MetAP-2
inhibition and increased caspase activity and the caspase
inhibitor, zVAD-fmk, preventing fumagillin-induced
apoptosis [14]. Therefore, MetAP-2 and caspase activity
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We also analyzed the effects of the putative angiogenesis
inhibitor CC5079 after systemic injection in the CAM
assay on the above pathways. Our results demonstrated
that p21 was significantly increased by treatment with
CC5079 compared to control. There was no significant
effect on MetAP-2 expression compared to controls, while
CC5079 increased expression of cleaved caspase-3 and
inhibited the expression of alpha v beta 3 (Figure
6A,6B,6C,6D). These results suggest a possible role of
CC5079 as an inducer of endothelial cell apoptosis per-
haps through a MetAP-2 independent pathway. Addi-
tional studies will now be pursued based on these leads to
further characterize the activity and mechanism of action
of CC5079.
In conclusion, we have described a modified version of
the CAM assay, which utilizes systemic injection of FITC-
dextran to create a quantitative measurement of vascular
density. In addition, XTT reagent can be utilized as a
complementary method to quantitatively measure
endothelial proliferation in the CAM after systemic or top-
ical administration of an anti-angiogenic or pro-ang-
iogenic agent. Finally, Layered Expression Scanning (LES)
may be very useful as a method to quantitatively measure
protein changes in response to anti-angiogenic and pro-
angiogenic agents in the CAM assay and therefore help to
correlate changes in vascular density with changes seen on
a molecular level. It is our hope that these described mod-
ifications will result in a single in vivo assay system that
will help investigators to better understand the molecular
mechanisms underlying the angiogenic response follow-
ing exposure to agents and may help in the identification
of novel targets and the design of novel therapeutics.
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